Open an account

Tango Therapeutics

TNGX · NASDAQ

$25.25+$1.72 (+7.31%)TodayMarket closed ·
Prev close $23.53

About TNGX

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The firm is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

Employees
137
Headquarters
Boston, Massachusetts
Listed
Sep 3, 2020
Sector
Health Care
Industry
Biotechnology
Website
tangotx.com

TNGX key statistics

Market cap
4.26B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.85M
Volume
2.68M
Open price
$23.51
High today
$25.35
Low today
$23.20
52 Week high
$34.39
52 Week low
$6.69

Tango Therapeutics (TNGX) at a glance

Tango Therapeutics (TNGX) last traded at $25.25, with a market cap of 4.26B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $23.20 and $25.35. The current price is 8.8% above the day's low and 0.4% below its high.

Volume so far is 2.68M shares, below the average of 3.85M shares a day.

Over the past year Tango Therapeutics has ranged from $6.69 to $34.39, and now sits 67% of the way up that range.

Tango Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.37 per share against an estimate of -$0.3248.

The average analyst price target is $46.00, 82.2% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

86%of 14 analyst ratings say Buy
  • Buy85.7%
  • Hold14.3%
  • Sell0.0%
Price target · 13 analystsAvg $46.00
Low
$24.24
Now
$25.25
High
$72.45

TNGX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 100.2% on average.

  1. Q3 FY24: reported -$0.27 per share against an estimate of -$0.3745
  2. Q4 FY24: reported -$0.35 per share against an estimate of -$0.3456
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.357
  4. Q2 FY25: reported -$0.35 per share against an estimate of -$0.3548
  5. Q3 FY25: reported $0.14 per share against an estimate of -$0.0538
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.3264
  7. Q1 FY26: reported -$0.32 per share against an estimate of -$0.3196
  8. Q2 FY26: reported -$0.37 per share against an estimate of -$0.3248

TNGX news

  • Press releaseGlobe Newswire

    NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

  • Shivdeep Dhaliwal

    Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today

  • Avi Kapoor

    Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings

  • Vandana Singh

    Why Is Tango Therapeutics Stock Soaring Monday?

  • Avi Kapoor

    Crude Oil Surges 3%; RBC Bearings Earnings Top Views

  • Press releaseGlobe Newswire

    The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Examining the Future: Tango Therapeutics's Earnings Outlook

Similar companies

Companies in the same industry as Tango Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.